Stock Events

Stock Events

Ocular Therapeutix 

€8.25
64
-€0.05-0.6% Tuesday 19:56

Statistics

Day High
8.45
Day Low
7.75
52W High
13.55
52W Low
5.82
Volume
4,194
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q4 2025
Q1 2026
Next
-0.34
-0.31
-0.28
-0.25
Expected EPS
-0.32002125
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0OT.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes with Ocular Therapeutix in the eye care market, particularly in treatments for eye diseases and conditions.
Novartis
NVS
Mkt Cap279.67B
Novartis provides advanced eye care treatments, including gene therapy for retinal diseases, directly competing with Ocular Therapeutix's eye disease treatments.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie, through its acquisition of Allergan, competes in the ophthalmology space, particularly in treatments for eye conditions that overlap with Ocular Therapeutix's portfolio.
Bausch Health Companies
BHC
Mkt Cap2.11B
Bausch Health Companies, through its eye health division, offers products that compete across a broad range of eye conditions treated by Ocular Therapeutix.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Vision Care division, competes in the market for eye health, offering products that can overlap with Ocular Therapeutix's therapeutic areas.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a presence in the ophthalmology market, competing indirectly with Ocular Therapeutix through its various treatments for eye diseases.
Regenxbio
RGNX
Mkt Cap470.75M
REGENXBIO is involved in gene therapy for eye diseases, representing a direct competitor to Ocular Therapeutix's approach to treating similar conditions.
EyePoint
EYPT
Mkt Cap1.16B
EyePoint Pharmaceuticals focuses on sustained release drug delivery for eye diseases, directly competing with Ocular Therapeutix's drug delivery technology.

About

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Show more...
CEO
Dr. Pravin U. Dugel M.D.
Employees
325
Country
United States
ISIN
US67576A1007

Listings

STU
DE
0OT.STU
F
DE
0OT.F
BOATS
BOATS
OCUL.BOATS
XNAS
US
OCUL

0 Comments

Share your thoughts

FAQ

What is Ocular Therapeutix stock price today?▼
The current price of 0OT.STU is €8.25 EUR — it has decreased by -0.6% in the past 24 hours. Watch Ocular Therapeutix stock price performance more closely on the chart.
What is Ocular Therapeutix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ocular Therapeutix stocks are traded under the ticker 0OT.STU.
Is Ocular Therapeutix stock price growing?▼
0OT.STU stock has risen by +5.77% compared to the previous week, the month change is a +12.18% rise, over the last year Ocular Therapeutix has showed a +31.37% increase.
When is the next Ocular Therapeutix earnings date?▼
Ocular Therapeutix is going to release the next earnings report on August 10, 2026.
What were Ocular Therapeutix earnings last quarter?▼
0OT.STU earnings for the last quarter are -0.34 EUR per share, whereas the estimation was -0.27 EUR resulting in a -27.07% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Ocular Therapeutix have?▼
As of May 06, 2026, the company has 325 employees.
In which sector is Ocular Therapeutix located?▼
Ocular Therapeutix operates in the Health & Wellness sector.
When did Ocular Therapeutix complete a stock split?▼
Ocular Therapeutix has not had any recent stock splits.
Where is Ocular Therapeutix headquartered?▼
Ocular Therapeutix is headquartered in Bedford, United States.